6.1 examples of small-molecule and peptide neurotransmitters. (part 1)

6.1 Examples of small-molecule and peptide neurotransmitters. (Part 1)

6.1 Examples of small-molecule and peptide neurotransmitters. (Part 2)

6.1 Examples of small-molecule and peptide neurotransmitters. (Part 3)

6.1 Examples of small-molecule and peptide neurotransmitters. (Part 4)

6.1 Examples of small-molecule and peptide neurotransmitters. (Part 5)

6.15 Neuropeptides vary in length, but usually contain between 3 and 36 amino acids.

5.5 Metabolism of small-molecule and peptide transmitters. (Part 1)

5.5 Metabolism of small-molecule and peptide transmitters. (Part 3)

5.5 Metabolism of small-molecule and peptide transmitters. (Part 4)

5.12 Differential release of neuropeptide and small-molecule co-transmitters.

6.2 Acetylcholine metabolism in cholinergic nerve terminals.

6.6 Glutamate synthesis and cycling between neurons and glia.

6.8 Synthesis, release, and reuptake of the neurotransmitters GABA and glycine. (Part 2)

6.8 Synthesis, release, and reuptake of the neurotransmitters GABA and glycine. (Part 1)

Figure 6.10 The biosynthetic pathway for the catecholamine neurotransmitters

Neurotransmitters and transporters: Dopamine factoids

•Dopamine is believed to be involved in motivation, reward, and reinforcement and many drugs of abuse affect dopaminergic synapses. Dopamine action in the synaptic cleft is terminated by the reuptake of dopamine into the nerve terminal or neighboring glia by a Na+ dependent dopamine transporter (DAT). Cocaine exerts its effects by binding to and inhibiting DAT which causes an increase in the amount of dopamine in the synaptic cleft.

•Amphetamine, another addictive drug, also inhibits DAT as well as the transporter for norepinephrine.

•The two major enzymes involved in the breakdown of dopamine are monoamine oxidase (MAO) and catechol O-methyltransferase (COMT). Inhibitors of these enzymes such as phenelzine and tranylcypromine are used clinically as antidepressants.

6.18 Synthesis, release, and termination of NO.

Box F Marijuana and the Brain (Part 1)

Box F Marijuana and the Brain (Part 2)

5.22 A neurotransmitter can affect a postsynaptic cell via two types of receptor proteins. (Part 2)

Figure 7.5 Types of GTP-binding proteins (Part 1)

Figure 7.6 Effector pathways associated with G-protein-coupled receptors

Figure 6.4 Muscarinic and other metabotropic receptors

5.22 A neurotransmitter can affect a postsynaptic cell via two types of receptor proteins. (Part 1)

6.4 The general architecture of ligand-gated receptors. (Part 1)

The families of ligand-gated receptors.

Glutamate receptor subtypes are named after the agonists that activate them:AMPA: a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionateNMDA: N-methyl-D-aspartateKainate: Kainic acid

Most central synapses have both AMPA and NMDA receptors

6.3 The structure of the nACh receptor/channel. (Part 2)

6.9 Ionotropic GABA receptors. (Part 2)

GABA acting on GABAARs usually hyperpolarizes cells because ECl is more negative than the resting potential, so Cl- flows into the cell. In some cases GABA can evoke depolarization instead of hyperpolarization in neurons. This can occur if the chloride equilibrium potential (ECl) is positive to the resting potential.

What controls where ECl is? It depends on intracellular chloride concentration, which appears to be regulated primarily by two transporters, an Na-K-Cl cotransporter (NKCC) that normally accumulates chloride and a K-Cl cotransporter (KCC) that normally extrudes chloride (for review, see Russell, 2000). Certain neurons and epithelial cells with ECl positive to the resting potential express NKCC, whereas neurons with an ECl negative to the resting potential express KCC2 (the neuron-specific isoform).

6.7 NMDA and AMPA/kainate receptors. (Part 1)

Figure 6.6 Postsynaptic responses mediated by ionotropic glutamate receptors (Part 2)

Figure 5.17 Activation of ACh receptors at neuromuscular synapses

Figure 5.18 The influence of the postsynaptic membrane potential on end plate currents

EPC=g(Vm-Erev)

5.16 The influence of the postsynaptic membrane potential on end plate currents. (Part 3)

Lower external Na+ Higher external K+

5.17 The effect of ion channel selectivity on the reversal potential. (Part 1)

EPC=g(Vmem – Erev)

5.17 The effect of ion channel selectivity on the reversal potential. (Part 2)

5.18 Na+ and K+ movements during EPCs and EPPs. (Part 1)

5.18 Na+ and K+ movements during EPCs and EPPs. (Part 2)

5.18 Na+ and K+ movements during EPCs and EPPs. (Part 3)

5.18 Na+ and K+ movements during EPCs and EPPs. (Part 4)

5.19 Reversal and threshold potentials determine postsynaptic excitation and inhibition. (Part 1)

5.19 Reversal and threshold potentials determine postsynaptic excitation and inhibition. (Part 2)

5.20 Summation of postsynaptic potentials. (Part 1)

Figure 5.22 Summation of postsynaptic potentials (Part 2)

In this example, ATP, norepinephrine, and neuropeptide Y (NPY) exert complex effects on smooth muscle. Stimulation of a sympathetic neuron causes three phases of contraction of a vascular smooth muscle cell. Phase 1-ATP binds to a P2X purinoceptor (a ligand-gated cation channel) leading to depolarization, activation of voltage-gated Ca2+ channels, increased [Ca2+]i, and the rapid phase of contraction. Phase 2-norepinephrine binds to an alpha 1-adrenergic receptor, which, via a Gq/PLC/IP3 cascade, leads to Ca2+ release from internal stores and the second phase of contraction. Phase 3-when present, NPY binds to a Y1 receptor and somehow causes an increase in [Ca2+]i and thus produces the slowest phase of contraction. ER, endoplasmic reticulum; IP3 inositol 1,4,5-triphosphate; PLC, phospolipase C.

© 2005 Elsevier

Unusual neurotransmitters: Adenosine triphosphate (ATP)

ATP is made from adenosine and packed into large dense core or small synaptic type vesicles. ATP is released along with another transmitter, or by itself. After release, ATPase and other enzymes break it down and adenosine can be taken up again.

In addition, acetylcholine (ACh) binds to M3 muscarinic receptors(G-protein linked) on endothelial cells, leading to production of NO, which also diffuses to the smooth muscle cell. Both sources of NO raise [cGMP]i in the smooth muscle cell and contribute to the first phase of relaxation. In the second phase, which tends to occur more with prolonged or intense stimulation, the neuropeptide VIP (or a related peptide) binds to receptors on the smooth muscle cell and causes a delayed relaxation via an increase in [cAMP]i or a decrease in [Ca2+ ]i. cGMP, cyclic guanosine monophosphate. Downloaded from: StudentConsult

© 2005 Elsevier

Unusual neurotransmitters: NONitric oxide is made from L-arginine and a cofactor, citrullline by the enzyme nitric oxide synthase.

Stimulation of a postganglionic parasympathetic neuron can cause complex effects on vascular smooth muscle cell. The first phase in this example is mediated by both nitric oxide (NO) and acetylcholine. The neuron releases NO, which diffuses to the smooth muscle cell.